Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact
Trond Espen Detlie, Marte Eide Jahnsen, Jørgen Jahnsen, Department of Gastroenterology, Akershus University Hospital, Lørenskog 1478, Norway
Trond Espen Detlie, Jonas Christoffer Lindstrøm, Bjørn Moum, Jørgen Jahnsen, Institute of Clinical Medicine, University of Oslo, Oslo 0316, Norway
Jonas Christoffer Lindstrøm, Health Services Research Unit, Akershus University Hospital, Lørenskog 1478, Norway
Elisabeth Finnes, Bjørn Moum, Division of Medicine, Department of Gastroenterology, Oslo University Hospital Ullevål, Oslo 0424, Norway
Heinz Zoller, Department of Medicine II, Gastroenterology and Hepatology, Medical University of Innsbruck, Innsbruck A-6020, Austria
Author contributions: Detlie TE, Moum B and Jahnsen J contributed responsible for the concept and design of the study, acquisition of data, analysis and interpretation of data, and drafting the article and revising it critically for important intellectual content; Lindstrøm JC and Zoller H performed analysis and interpretation of data, and contributed critical revision of the manuscript for important intellectual content; Jahnsen ME and Finnes E contributed acquisition of data and critical revision of the manuscript for important intellectual content; Moum B and Jahnsen J contributed equally as senior authors; all the authors read and approved the final version of the manuscript.
Institutional review board statement: The study was reviewed and approved by the Regionale Komiteer for Medisinsk og Helsefaglig Forskningsetikk (REK) in Helse Sør-Øst, Norway/Regional Ethics Committee from the South-East Health Region of Norway.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: Detlie TE has served as a speaker, consultant or advisory board member for AbbVie, Ferring, Pfizer, Pharmacosmos, Tillotts, and Vifor Pharma. He has received unrestricted research grants from AbbVie, and Pharmacosmos. Jahnsen ME has received lecture fees from Pharmacosmos. Zoller H has served as a speaker, consultant or advisory board member for AbbVie, BMS, Gilead, MSD, Merck, Merz, Novartis, Pharmacosmos, and Vifor Pharma. Moum B has served as a speaker, consultant or advisory board member for AbbVie, Ferring, Janssen, Roche, and Takeda. Jahnsen J has served as a speaker, consultant or advisory board member for AbbVie, Astro Pharma, Boehringer Ingelheim, BMS, Celltrion, Ferring, Hikma, Janssen, Meda, MSD, Napp Pharma, Novartis, Orion Pharma, Pfizer, Pharmacosmos, Roche, Takeda, Tillotts, and Sandoz. The other authors have no disclosures.
Data sharing statement: The data underlying this article were provided by Akershus University Hospital and Oslo University Hospital Ullevål by permission. Data will be shared on request to the corresponding author with permission of Akershus University Hospital and Oslo University Hospital Ullevål.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Trond Espen Detlie, MD, Academic Fellow, Academic Research, Consultant Physician-Scientist, Doctor, Department of Gastroenterology, Akershus University Hospital, Sykehusveien 25, Lørenskog 1478, Norway. firstname.lastname@example.org
Received: January 28, 2021
Peer-review started: January 28, 2021
First decision: March 6, 2021
Revised: March 19, 2021
Accepted: April 21, 2021
Article in press: April 21, 2021
Published online: May 7, 2021